According to studies by Zeng et al., among 408 CRC patients, 33.1% (135) had KRAS mutations in exon 2, while NRAS mutations in exons 2 and 3 were found in 2.4% of patients (n = 10) [36]. Here, KRAS is linked to colorectal carcinoma.